Cancer-related and treatment-related fatigue

被引:129
作者
Wang, Xin Shelley [1 ]
Woodruff, Jeanie F. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
Cancer-related fatigue; Gynecological cancer; Patient-reported outcomes; Brief Fatigue Inventory; DOUBLE-BLIND TRIAL; QUALITY-OF-LIFE; PATIENTS RECEIVING CHEMOTHERAPY; RECURRENT EPITHELIAL OVARIAN; GYNECOLOGIC-ONCOLOGY-GROUP; CLINICAL-TRIALS; CHEMORADIATION THERAPY; MULTIPLE-SCLEROSIS; SYMPTOM BURDEN; FALLOPIAN-TUBE;
D O I
10.1016/j.ygyno.2014.10.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fatigue is a distressing and persistent symptom for patients with gynecological cancer and for survivors. Debilitating cancer-related fatigue (CRF) is produced by both the disease and its treatment. Although awareness and study of CRF have grown in recent years, consistent assessment has not been a priority in routine medical practice. The pathophysiological mechanisms that induce CRF remain unclear, and effective pharmacological interventions have yet to be established. Based on the literature and our own research results, this review focuses on recent progress toward understanding the nature and causes of CRF and on several promising treatment modalities. Given the prevalence and severity of CRF in the gynecological cancer patient population, establishing standardized fatigue measurement and management methods in routine clinical oncology care is of utmost importance. Whether CRF has an underlying inflammatory cause is still hypothetical, however, and no mechanism-driven symptom intervention is currently in clinical use, even though the development of such interventions would provide patients with greater symptom control. Advancing translational and clinical fatigue research will require anatomical pathway studies and well-designed clinical investigations that focus on the development of mechanism-driven interventions based on physiological-behavioral fatigue research, implementation of guidelines for experimental designs, and discovery of biomarkers identifying individuals at high risk for CRF. Validated patient-reported outcomes measures are an essential component of such clinical studies. Because numerous subscales, unidimensional measures, and multidimensional measures exist, clinicians and researchers should consider individual circumstances, good clinical practice, and research goals as guides for choosing the most appropriate fatigue measurement tool. Additionally, education about CRF should be made available to all patients and their caregivers, as accurate and age-appropriate information about conditions like CRF can alleviate much of the stress and anxiety brought on by poor communication about this distressing condition. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:446 / 452
页数:7
相关论文
共 71 条
  • [1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY
    AARONSON, NK
    AHMEDZAI, S
    BERGMAN, B
    BULLINGER, M
    CULL, A
    DUEZ, NJ
    FILIBERTI, A
    FLECHTNER, H
    FLEISHMAN, SB
    DEHAES, JCJM
    KAASA, S
    KLEE, M
    OSOBA, D
    RAZAVI, D
    ROFE, PB
    SCHRAUB, S
    SNEEUW, K
    SULLIVAN, M
    TAKEDA, F
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) : 365 - 376
  • [2] A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study
    Alvarez, Ronald D.
    Sill, Michael W.
    Davidson, Susan A.
    Muller, Carolyn Y.
    Bender, David P.
    DeBernardo, Robert L.
    Behbakht, Kian
    Huh, Warner K.
    [J]. GYNECOLOGIC ONCOLOGY, 2014, 133 (03) : 433 - 438
  • [3] Fatigue in women receiving intraperitoneal chemotherapy for ovarian cancer: A review of contributing factors
    Anderson, Nancy J.
    Hacker, Eileen D.
    [J]. CLINICAL JOURNAL OF ONCOLOGY NURSING, 2008, 12 (03) : 445 - 454
  • [4] Reliability of adverse symptom event reporting by clinicians
    Atkinson, Thomas M.
    Li, Yuelin
    Coffey, Charles W.
    Sit, Laura
    Shaw, Mary
    Lavene, Dawn
    Bennett, Antonia V.
    Fruscione, Mike
    Rogak, Lauren
    Hay, Jennifer
    Goenen, Mithat
    Schrag, Deborah
    Basch, Ethan
    [J]. QUALITY OF LIFE RESEARCH, 2012, 21 (07) : 1159 - 1164
  • [5] ASCPRO Recommendations for the Assessment of Fatigue as an Outcome in Clinical Trials
    Barsevick, Andrea M.
    Cleeland, Charles S.
    Manning, Donald C.
    O'Mara, Ann M.
    Reeve, Bryce B.
    Scott, Jane A.
    Sloan, Jeff A.
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2010, 39 (06) : 1086 - 1099
  • [6] Wisconsin Ginseng (Panax quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind Trial, N07C2
    Barton, Debra L.
    Liu, Heshan
    Dakhil, Shaker R.
    Linquist, Breanna
    Sloan, Jeff A.
    Nichols, Craig R.
    McGinn, Travis W.
    Stella, Philip J.
    Seeger, Grant R.
    Sood, Amit
    Loprinzi, Charles L.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (16): : 1230 - 1238
  • [7] Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes
    Basch, Ethan
    Jia, Xiaoyu
    Heller, Glenn
    Barz, Allison
    Sit, Laura
    Fruscione, Michael
    Appawu, Mark
    Iasonos, Alexia
    Atkinson, Thomas
    Goldfarb, Shari
    Culkin, Ann
    Kris, Mark G.
    Schrag, Deborah
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (23): : 1624 - 1632
  • [8] Yoga reduces inflammatory signaling in fatigued breast cancer survivors: A randomized controlled trial
    Bower, Julienne E.
    Greendale, Gail
    Crosswell, Alexandra D.
    Garet, Deborah
    Sternlieb, Beth
    Ganz, Patricia A.
    Irwin, Michael R.
    Olmstead, Richard
    Arevalo, Jesusa
    Cole, Steve W.
    [J]. PSYCHONEUROENDOCRINOLOGY, 2014, 43 : 20 - 29
  • [9] Inflammation and Behavioral Symptoms After Breast Cancer Treatment: Do Fatigue, Depression, and Sleep Disturbance Share a Common Underlying Mechanism?
    Bower, Julienne E.
    Ganz, Patricia A.
    Irwin, Michael R.
    Kwan, Lorna
    Breen, Elizabeth C.
    Cole, Steve W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (26) : 3517 - 3522
  • [10] Fatigue and gene expression in human leukocytes: Increased NF-κB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue
    Bower, Julienne E.
    Ganz, Patricia A.
    Irwin, Michael R.
    Arevalo, Jesusa M. G.
    Cole, Steve W.
    [J]. BRAIN BEHAVIOR AND IMMUNITY, 2011, 25 (01) : 147 - 150